Lymphoma Clinical Trials

Showing 1541-1560 of 2,926 trials

COMPLETED

A Survey Exploring Health and Screening Tests in People Treated for Hodgkin Lymphoma

NCT04996862

A survey of health beliefs and cancer screening behaviour and intentions in Hodgkin lymphoma survivors

Hodgkin Lymphoma

The Christie NHS Foundation Trust165 participantsStarted Jun 2021

Manchester, United Kingdom

UNKNOWNPhase 2

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

NCT04948788

The study is evaluating the efficacy, and safety of SHR1459 combined with YY-20394 for Recurrent and refractory B-cell non-Hodgkin's lymphoma in adults.

Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Jiangsu HengRui Medicine Co., Ltd.102 participantsStarted Oct 2021

Shanghai, Shanghai Municipality, China

TERMINATEDEARLY Phase 1

A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

NCT03585725

This is a A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

Follicular LymphomaMantle Cell Lymphoma

Weill Medical College of Cornell University3 participantsStarted Sep 2018

New York, New York, United States

COMPLETEDPhase 2

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

NCT02433795

This study will be conducted to evaluate the efficacy of Bendamustine Plus Rituximab (BR) in patients with relapsed or progressive Marginal Zone B-cell Lymphoma (MZBCL).

Marginal Zone B-cell Lymphoma

Seoul National University Hospital27 participantsStarted May 2015

Jeonju, Jeollabuk-do, South Korea • Anyang-si, South Korea • Daejeon, South Korea +8 more locations

A Survey Exploring Health and Screening Tests in People Treated for Hodgkin Lymphoma

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

Related Searches

Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma

Childhood Acute Lymphoblastic Leukaemia: Follow-Up

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma

R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma